Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones

被引：14

作者：

Behary, Preeshila ^{[1
]}

Cegla, Jaimini ^{[1
]}

Tan, Tricia M. ^{[1
]}

Bloom, Stephen R. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Diabet Endocrinol & Metab, London W12 0NN, England

来源：

POSTGRADUATE MEDICINE | 2015年 / 127卷 / 05期

基金：

英国生物技术与生命科学研究理事会;

关键词：

Obesity; lifestyle management; bariatric surgery; drugs; gut hormones; Y GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE-1; TERM WEIGHT-LOSS; NALTREXONE SR/BUPROPION SR; LOW-CALORIE-DIET; BODY-MASS INDEX; FOOD-INTAKE; ENERGY-EXPENDITURE; PANCREATIC-POLYPEPTIDE; PHYSICAL-ACTIVITY;

D O I：

10.1080/00325481.2015.1048181

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity is on the rise and the pursuit of efficient and safe treatment is ongoing. Available anti-obesity medical therapies have so far proved to be disappointing, whereas bariatric surgery is leading the way and offers long-term health benefits. Part of the success of bariatric surgery is thought to be mediated by gut hormones. A better understanding of the role of gut hormones within the gut-brain signaling pathway in the control of hunger, satiety, and energy homeostasis, has led to their therapeutic exploitation as possible anti-obesity drugs. In this review, we provide a summary of currently available treatment options for obesity from simple lifestyle modifications and bariatric surgery to traditional and novel medical therapies.

引用

页码：494 / 502

页数：9

共 119 条

[1] Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch [J].

Aasheim, Erlend T. ;

Bjorkman, Sofia ;

Sovik, Torgeir T. ;

Engstrom, My ;

Hanvold, Susanna E. ;

Mala, Tom ;

Olbers, Torsten ;

Bohmer, Thomas .

AMERICAN JOURNAL OF CLINICAL NUTRITION, 2009, 90 (01) :15-22

[2]

Ahmad Ahmir, 2014, JRSM Open, V5, p2042533313512479, DOI [10.1177/2042533313517689, 10.1177/2042533313512479]

[3]

[Anonymous], 2008, Physical Activity Guidelines for Americans

[4]

[Anonymous], 2014, Obesity: Identification

[5]

[Anonymous], OBESITY SURG

[6]

[Anonymous], 2002, REP ADV COMM HLTH RE

[7] A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II) [J].

Apovian, Caroline M. ;

Aronne, Louis ;

Rubino, Domenica ;

Still, Christopher ;

Wyatt, Holly ;

Burns, Colleen ;

Kim, Dennis ;

Dunayevich, Eduardo .

OBESITY, 2013, 21 (05) :935-943

[8] Characterization of the effects of pancreatic polypeptide in the regulation of energy balance [J].

Asakawa, A ;

Inui, A ;

Yuzuriha, H ;

Ueno, N ;

Katsuura, G ;

Fujimiya, M ;

Fujino, MA ;

Niijima, A ;

Meguid, MM ;

Kasuga, M .

GASTROENTEROLOGY, 2003, 124 (05) :1325-1336

[9] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [J].

Astrup, A. ;

Carraro, R. ;

Finer, N. ;

Harper, A. ;

Kunesova, M. ;

Lean, M. E. J. ;

Niskanen, L. ;

Rasmussen, M. F. ;

Rissanen, A. ;

Rossner, S. ;

Savolainen, M. J. ;

Van Gaal, L. .

INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) :843-854

[10] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

← 1 2 3 4 5 6 7 8 9 10 →